Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7538168 | 0.82 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL149727 | 0.82 | SLC6A4 (0.39) | ALDH1A1CYP1A2CYP2C19P2RX7KDM4E | |
| SCHEMBL531667 | 0.79 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL8290760 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL697564 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL2351920 | 0.77 | IDO1 (0.61) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL211919 | 0.77 | PNMT (0.48) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL2089246 | 0.77 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL17552707 | 0.77 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 | |
| SCHEMBL13647058 | 0.77 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2RAB9ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019025153-A1 | USE OF SUBSTITUTED N-SULFONYL-N'-ARYL DIAMINOALKANES AND N-SULFONYL-N'-HETEROARYL DIAMINOALKANES OR SALTS THEREOF FOR INCREASING THE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | claimed |
| WO-2012100436-A1 | COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF | CUREGENIX INC. (CN) | 2012-08-02 | — | — | WO | claimed |
| EP-1599201-B1 | SELECTIVE NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | claimed |
| US-7411073-B2 | Selective non-steroidal glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | MERCK SHARP & DOHME CORP. | 2006-04-06 | — | — | US | claimed |
| WO-2019025153-A1 | USE OF SUBSTITUTED N-SULFONYL-N'-ARYL DIAMINOALKANES AND N-SULFONYL-N'-HETEROARYL DIAMINOALKANES OR SALTS THEREOF FOR INCREASING THE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| EP-3074377-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016026830-A1 | NOVEL FUNGICIDAL PYRAZOLE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | WO | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| CN-1478082-A | Pyrimidine compound and application thereof | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
| EP-0421227-B1 | 1-Hydroxy-1,2,4-triazole derivatives and fungicides containing them and growth regulators | BASF AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| US-5081142-A | DERIVATIVES OF 1-HYDROXY-1,2,4-TRIAZOLE AND FUNGICIDES AND GROWTH REGULATORS CONTAINING THEM | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-14 | — | — | US | disclosed |
| EP-0421227-A2 | 1-Hydroxy-1,2,4-triazole derivatives and fungicides containing them and growth regulators | BASF Aktiengesellschaft (DE) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | ALDH1A1 654/4885SMN1; SMN2 2180/4885RAB9A 1090/4885 |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | ALDH1A1 1362/4885SMN1; SMN2 4093/4885RAB9A 1514/4885 |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | NR3C1, NR3C2, NR5A1 | ALDH1A1 1631/4885SMN1; SMN2 4714/4885RAB9A 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.